Welcome to CSNpharm! For Research Use Only!
Home +1-708-781-1677

c-Met/HGFR

c-Met/HGFR

Cat. No. Product Name CAS No. Information
CSN17399 Tyrosine Kinase Inhibitor 1021950-26-4 Tyrosine kinase inhibitor is a drug used for advanced renal cell carcinoma
CSN12917 Tivantinib 905854-02-6 Tivantinib is an non-ATP-competitive c-Met inhibitor with Ki of 0355 M with little activity to Ron and no inhibition to EGFR InsR PDGFR or FGFR14
CSN16106 SGX-523   1022150-57-7 SGX-523 is a potent and selective c-Met inhibitor with IC50 of 4 nM
CSN17517 SCR-1481B1 1174161-86-4 SCR-1481B1 is a potent compound that has activity against cancers dependent upon Met activation and also has activity against cancers as a VEGFR inhibitor
CSN17684 Savolitinib 1313725-88-0 Savolitinib is an orally bioavailable inhibitor of the c-Met receptor tyrosine kinase (IC50 5 nM) with potential antineoplastic activity.
CSN20348 SAR125844 1116743-46-4 SAR125844 is a potent and highly selective c-Met inhibitor with potential antineoplastic activity
CSN19153 S49076 1265965-22-7 S49076 is a potent inhibitor of MET AXLMER and FGFRs
CSN12934 PHA-665752 477575-56-7 PHA-665752 is a potent selective and ATP-competitive c-Met inhibitor with IC50 of 9 nM
CSN18635 PF-04217903 Methanesulfonate 956906-93-7 PF-04217903 Methanesulfonate is a highlu selective c-Met inhibitor with IC50 of 48 nM
CSN16129 PF-04217903 956905-27-4 PF-04217903 is a selective ATP-competitive c-Met inhibitor with IC50 of 48 nM susceptible to oncogenic mutations no activity to Y1230C mutant
CSN17159 NVP-BVU972 1185763-69-2 NVP-BVU972 is a potent and selective c-Met inhibitor with IC50 of 14 nM with antitumor effects
CSN23685 Ningetinib Tosylate 1394820-77-9 Ningetinib tosylate is an inhibitor of tyrosine kinase inhibitor TKI and the IC50 for c-Met VEGFR2 and Axl are 67 nM 19 nM and 10 nM respectively
CSN17658 MK-8033 HCl 1283000-43-0 MK8033 hydrochloride is a specific dual ATP competitive c-MetRon inhibitor IC501 nM Wt c-Met under investigation as a treatment for cancer
CSN13613 MK-8033 1001917-37-8 MK-8033 is a specific dual ATP competitive c-MetRon inhibitor IC501 nM Wt c-Met under investigation as a treatment for cancer
CSN16566 MK-2461 917879-39-1 MK-2461 is a potent and multi-targeted inhibitor for c-Met with IC50 of 04-25 nM also inhibits FGFR123 KDR TrkAB and Flt4 with IC50 of 653950 nM 44 nM 4661 nM and 78 nM respectively
CSN13734 LY2801653 1206799-15-6 LY2801653 is a potent and orally bioavailable inhibitor of c-MET kinase with Ki of 2 nM
CSN17560 LY2801653 2HCl 1206801-37-7 LY2801653 dihydrochloride is a potent orally bioavailable small-molecule inhibitor of c-MET kinase Ki 2 nM
CSN22436 JNJ-38877618 943540-74-7 JNJ-38877618 is a potent highly selective orally bioavailable Met kinase inhibitor with IC50s of 2 and 3 nM for wild type and mutant Met respectively
CSN12936 JNJ-38877605 943540-75-8 JNJ-38877605 is an ATP-competitive inhibitor of c-Met with IC50 of 4 nM
CSN15776 INC28060 1029712-80-8 INCB28060 is a potent and selective c-MET kinase inhibitor. INCB28060 inhibits c-MET kinase activity with an average IC50 of 0.13 nM.
CSN15829 Golvatinib 928037-13-2 Golvatinib is a dual c-Met and VEGFR-2 inhibitor with IC50 of 14 nM and 16 nM
CSN17479 Glesatinib HCl 1123838-51-6 Glesatinib hydrochloride is an inhibitor of the MET and Axl receptor tyrosine kinase pathways which drive tumour growth when altered
CSN12685 Foretinib 849217-64-7 Foretinib is an ATP-competitive inhibitor of HGFR and VEGFR, mostly for Met and KDR with IC50 of 0.4 nM and 0.9 nM in cell-free assays. Foretinib is less potent against Ron, Flt-134, Kit, PDGFR and Tie-2, and with little activity to FGFR1 and EGFR.
CSN15875 Tepotinib     1100598-32-0 EMD 1214063 is a potent and selective c-Met inhibitor with IC50 of 4 nM 200-fold selective for c-Met than IRAK4 TrkA Axl IRAK1 and Mer
CSN22378 c-Met-IN-2 1635406-73-3 c-Met-IN-2 is a potent selective and orally available c-Met inhibitor with an IC50 of 06 nM with antitumor activity
CSN16262 c-Met Inhibitor 1 1357072-61-7 c-Met Inhibitor 1 is a c-Met receptor signaling pathway inhibitor used for the treatment of cancer including gastric glioblastoma and pancreatic cancer
CSN16525 BMS-794833 1174046-72-0 BMS-794833 is a potent ATP competitive inhibitor of Met and VEGFR2 with IC50 of 17 and 15 nM
CSN13471 BMS-777607   1025720-94-8 BMS-777607 is a Met-related inhibitor for c-Met Axl Ron and Tyro3 with IC50 of 39 nM 11 nM 18 nM and 43 nM being 40-fold selective for Met-related targets versus Lck VEGFR-2 and TrkAB and more than 500-fold greater selectivity versus all other receptor and non receptor kinases
CSN17199 AMG-458 913376-83-7 AMG-458 is a potent c-Met inhibitor with Ki of 12 nM 350-fold selectivity for c-Met than VEGFR2 in cells
CSN17516 AMG-337 1173699-31-4 AMG-337 is a potent highly selective and ATP-competitive MET kinase inhibitor with an IC50 of 5nM in enzymatic assays
CSN16548 AMG-208 1002304-34-8 AMG-208 is a potent small molecular c-Met inhibitor with an IC50 of 93 nM
CSN16259 Altiratinib 1345847-93-9 Altiratinib is a c-METTIE-2VEGFR inhibitor which effectively reduce tumor burden in vivo and block c-MET pTyr1349-mediated signaling cell growth and migration as compared with a HGF antagonist in vitro
CSN23572 Norcantharidin 29745-04-8
CSN23729 PLB-1001 1440964-89-5
<< PREV 1 2 NEXT >>